97 related articles for article (PubMed ID: 24457590)
1. Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy.
Mikami K; Jorge RE; Moser DJ; Arndt S; Jang M; Solodkin A; Small SL; Fonzetti P; Hegel MT; Robinson RG
J Neuropsychiatry Clin Neurosci; 2014; 26(4):323-8. PubMed ID: 24457590
[TBL] [Abstract][Full Text] [Related]
2. Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
Allgulander C; Florea I; Huusom AK
Int J Neuropsychopharmacol; 2006 Oct; 9(5):495-505. PubMed ID: 16316482
[TBL] [Abstract][Full Text] [Related]
3. Prevention of poststroke apathy using escitalopram or problem-solving therapy.
Mikami K; Jorge RE; Moser DJ; Arndt S; Jang M; Solodkin A; Small SL; Fonzetti P; Hegel MT; Robinson RG
Am J Geriatr Psychiatry; 2013 Sep; 21(9):855-62. PubMed ID: 23930743
[TBL] [Abstract][Full Text] [Related]
4. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
5. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
Bystritsky A; Kerwin L; Feusner JD; Vapnik T
Psychopharmacol Bull; 2008; 41(1):46-51. PubMed ID: 18362870
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram.
Robinson RG; Jorge RE; Long J
Am J Geriatr Psychiatry; 2017 May; 25(5):512-519. PubMed ID: 28029510
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.
Robinson RG; Jorge RE; Moser DJ; Acion L; Solodkin A; Small SL; Fonzetti P; Hegel M; Arndt S
JAMA; 2008 May; 299(20):2391-400. PubMed ID: 18505948
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
10. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Bech P; Lönn SL; Overø KF
J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
[TBL] [Abstract][Full Text] [Related]
11. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
12. The effect of escitalopram on sleep problems in depressed patients.
Lader M; Andersen HF; Baekdal T
Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
[TBL] [Abstract][Full Text] [Related]
13. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
[TBL] [Abstract][Full Text] [Related]
14. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Demyttenaere K; Andersen HF; Reines EH
Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults.
Wetherell JL; Petkus AJ; White KS; Nguyen H; Kornblith S; Andreescu C; Zisook S; Lenze EJ
Am J Psychiatry; 2013 Jul; 170(7):782-9. PubMed ID: 23680817
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions.
Stein DJ; Kasper S; Andersen EW; Nil R; Lader M
Depress Anxiety; 2004; 20(4):175-81. PubMed ID: 15643634
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Allgulander C; Jørgensen T; Wade A; François C; Despiegel N; Auquier P; Toumi M
Curr Med Res Opin; 2007 Oct; 23(10):2543-9. PubMed ID: 17825130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
